(CercleFinance.com) – Genfit today announced the results of its Combined General Meeting convened for May 25, 2022. The quorum met on first call was 25.16% and enabled all of the draft resolutions for the Meeting proposed by the Board of Directors.
Jean-François Mouney, Chairman of the Board of Directors of Genfit, commented: ‘I also welcome the arrival on our Board of Directors of Steven Hildemann, Executive Vice-President and Chief Medical Officer of Ipsen. This appointment is part of the strategic partnership agreement signed with Ipsen at the end of 2021, and will be a valuable asset for Genfit in the future, since Steven Hildemann’s experience and skills in the field of industrial Pharmaceuticals are now supplementing those already present on the Board. ‘
Dr. Steven Hildemann, MD., PhD, has been Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance of Ipsen since March 1, 2020. With more than 20 years of industry experience pharmaceutical industry and 10 years as a university doctor-researcher, since this appointment he has directed Ipsen’s activities relating to Global Medical Affairs, Pharmacovigilance and Patient Relationship Management.